We use tools, such as cookies, to enable essential services and functionality on our site. We also use this to collect data on how our visitors interact with our site, products and services. By clicking accept, you agree to our use of these tools for advertising, analytics and support. I Accept Privacy Policy Cookie Policy

immunodiagnosticsystems
0
immunodiagnosticsystems
0
  • About IDS
    • Company Overview
    • Corporate History
    • Strategic Vision
    • Board of Directors
    • IDS Worldwide
    • IDS Values
    • Careers
    • News and Events
  • Products
    Automated
    Manual
  • Instrumentation
    • IDS-iSYS Multi-Discipline Automated System
    • Specifications
    • Service & Support
  • Clinical Areas
    Bone Metabolism
    Calcium Metabolism
    CKD-MBD
    Growth
    Cartilage Markers
    Fertility
    Autoimmunity
    Infectious Diseases
    Allergy
    Covid-19
    Sarcoidosis Assays
    Therapeutic Drug Monitoring
    Hypertension Immunoassays
  • Research Areas
    Animal Research
    Bone Turnover Markers
    Other Research Areas
  • COVID-19 Tests
  • Investor Relations
  • Contact
immunodiagnosticsystems
+44 (0)191 5190660
0

Quotes

  • About IDS
    • Company Overview
    • Corporate History
    • Strategic Vision
    • Board of Directors
    • IDS Worldwide
    • IDS Values
    • Careers
    • News and Events
  • Products
    Automated
    Manual
  • Instrumentation
    • IDS-iSYS Multi-Discipline Automated System
    • Specifications
    • Service & Support
  • Clinical Areas
    Bone Metabolism
    Calcium Metabolism
    CKD-MBD
    Growth
    Cartilage Markers
    Fertility
    Autoimmunity
    Infectious Diseases
    Allergy
    Covid-19
    Sarcoidosis Assays
    Therapeutic Drug Monitoring
    Hypertension Immunoassays
  • Research Areas
    Animal Research
    Bone Turnover Markers
    Other Research Areas
  • COVID-19 Tests
  • Investor Relations
  • Contact

Month: March 2010

  • All News
  • Company News
  • Event News
  • Industry News
  • Product News
A man laughing whilst stroking his chin

Total Voting Rights

In conformity with the FSA’s Disclosure and Transparency Rules, the Company notifies the market of the following: As at the date of this announcement, the Company’s issued share capital consists of 27,854,566 ordinary shares with a nominal value of 2 pence each (‘Ordinary Shares’), with voting rights. Download for More Information

IDS assay long exposure image

New Specialist Assays Launched for IDS-ISYS

Immunodiagnostic Systems Holdings plc (“IDS”), a leading producer of diagnostic testing kits for the clinical and research markets, announces the launch of three newly-developed fully-automated immunoassays for use on the IDS-iSYS Immunoanalyser. Parathyroid hormone (“PTH”) calcium biomarker Insulin-like Growth Factor I (IGF-I) Osteocalcin bone protein These launches bring the IDS-iSYS product range to a total […]

Leaves against a sunny sky

Directors’ Dealings March 2010

The Company announces that on 18 March 2010, Roger Duggan, Chief Executive Officer, transferred 15,168 ordinary shares of 2 pence each in the Company (‘Ordinary Shares’) to his SIPP at a price of 764.75 pence per share. Following this transfer, Mr Duggan’s notifiable interest in the Company remains unchanged at 2,276,187 Ordinary Shares representing 8.2 […]

  • About Us
  • Products
  • Instrumentation
  • Clinical Areas
  • Research Areas
  • Investor Relations
  • Contact
Connect with us
Connect with us
Connect with us
  • Careers
  • News & Events
  • Sitemap
  • Cookie Policy
  • Terms of Use Policy
  • Privacy Policy
  • Acceptable Use Policy
  • Purchasing T&Cs
  • Terms of Sale
IDS PLC © 2017 Immunodiagnostic Systems. All Rights Reserved. IDS is a listed company, traded on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange. Please note our sites uses cookies for content personalisation, please review our cookie policy for further information.

To receive our Newsletter Document Name, please provide us with your following details:

To receive our Newsletter, please provide us with your following details: